It was hypothesized that oral vitamin B12 supplementation
in patients with serum B12 deficiency following
enterocystoplasty is a long-term effective treatment with
which to maintain normal B12 serum levels. Additionally, in
a separate investigation designed to obtain a larger cohort,
it was sought to determine if the underlying disease state
was a risk factor for developing B12 deficiency in order to
identify patients at higher risk of B12 deficiency following
enterocystoplasty. Two separate cohorts were reviewed to
assess the long-term durability of oral B12 therapy, and to
assess the impact of underlying diagnosis on predicting B12
deficiency. While the two cohorts were conceived as independent
investigations, the subject matter was the same.
These results were reported together in an effort to
maximize the strength of the B12 literature, while avoiding
duplicity.